drugset / Trial / NCT05618041
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Recruiting
50 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Taihe Chunyu Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
Timeline
- Start
- 2022-09-07
- Primary completion
- 2027-09-06
- Completion
- 2027-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T | Cell therapy | — | — |
| Subject | CD19 CAR-T | Cell therapy | — | — |
| Subject | CD20 CAR-T | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |